Network pharmacological analysis of Xiao-Xu-Ming decoction against ischemic stroke and verification of its mechanism of anti-inflammation and neurovascular protection in vivo

doi:10.5246/jcps.2022.05.030

Abstract

Abstract:

Stroke is a major cause of severe disability and death. Xiao-Xu-Ming decoction (XXMD) is an effective prescription for stroke and its sequelae, while its effective ingredients and mechanism are still unclear. In the present study, we aimed to explore the effective ingredients and mechanism of XXMD in treating cerebral ischemia using network pharmacology. The main chemical components and targets of 12 herbs of?XXMD were obtained by the TCMSP database and analysis platform database. The active components in XXMD were screened according to oral utilization and drug-like properties. Then, the cerebral ischemia targets were obtained through GeneCards, OMIM, TTD, Diligent and Drugbank databases. We analyzed the pathophysiological processes and pathways involved in the treatment of cerebral ischemia with XXMD by using the Metascape data analysis platform. Results showed that β-sitosterol, kaempferol, quercetin, stigmasterol, wogonin, and catechins might be the potential core active ingredients of XXMD in the treatment of cerebral ischemia. The therapeutic effect of XXMD on stroke was mainly exerted through regulating neuroinflammatory response and neurovascular protection. Furthermore, the anti-neuroinflammation and neurovascular protection of XXMD were further confirmed using?cerebral ischemia rats. Collectively, our findings revealed that the mechanism of XXMD on the treatment of cerebral ischemia was related to anti-neuroinflammation and neurovascular protection.

Key words: Xiao-Xu-Ming decoction, Cerebral ischemia, Network pharmacology, Neuroprotection

Supporting:

Yinglin Yang, Shanshan Zhang, Man Liu, Dongni Liu, Yuehua Wang, Guanhua Du. Network pharmacological analysis of Xiao-Xu-Ming decoction against ischemic stroke and verification of its mechanism of anti-inflammation and neurovascular protection in vivo[J]. Journal of Chinese Pharmaceutical Sciences, 2022, 31(5): 343-359.

Figures/Tables 6

References 40

[1]	Liu, L.L.; Chen, H.P.; Jin, J.; Tang, Z.B.; Yin, P.Q.; Zhong, D.; Li, G.Z. Melatonin ameliorates cerebral ischemia/reperfusion injury through SIRT3 activation. Life Sci. 2019, 239, 117036.
[2]	Shi, K.B.; Tian, D.C.; Li, Z.G.; Ducruet, A.F.; Lawton, M.T.; Shi, F.D. Global brain inflammation in stroke. Lancet Neurol. 2019, 18, 1058–1066.
[3]	Jayaraj, R.L.; Azimullah, S.; Beiram, R.; Jalal, F.Y.; Rosenberg, G.A. Neuroinflammation: friend and foe for ischemic stroke. J. Neuroinflammation. 2019, 16, 142.
[4]	Anrather, J.; Iadecola, C. Inflammation and stroke: an overview. Neurotherapeutics. 2016, 13, 661–670.
[5]	Xie, P.; Deng, M.; Sun, Q.G.; Ma, Y.G.; Zhou, Y.; Ming, J.H.; Chen, Q.; Liu, S.Q.; Liu, J.Q.; Cai, J.; Wu, F. Therapeutic effect of transplantation of human bone marrow‑derived mesenchymal stem cells on neuron regeneration in a rat model of middle cerebral artery occlusion. Mol. Med. Rep. 2019, 20, 3065–3074.
[6]	Marques, B.L.; Carvalho, G.A.; Freitas, E.M.M.; Chiareli, R.A.; Barbosa, T.G.; di Araújo, A.G.P.; Nogueira, Y.L.; Ribeiro, R.I.; Parreira, R.C.; Vieira, M.S.; Resende, R.R.; Gomez, R.S.; Oliveira-Lima, O.C.; Pinto, M.C.X. The role of neurogenesis in neurorepair after ischemic stroke. Semin. Cell Dev. Biol. 2019, 95, 98–110.
[7]	Zhai, Z.Y.; Feng, J. Constraint-induced movement therapy enhances angiogenesis and neurogenesis after cerebral ischemia/reperfusion. Neural Regen. Res. 2019, 14, 1743–1754.
[8]	Venkat, P.; Shen, Y.; Chopp, M.; Chen, J.L. Cell-based and pharmacological neurorestorative therapies for ischemic stroke. Neuropharmacology. 2018, 134, 310–322.
[9]	Hu, Y.Z.; Wang, J. Interactions between clopidogrel and traditional Chinese medicine. J. Thromb. Thrombolysis. 2019, 48, 491–499.
[10]	Niu, B.X.; Zhang, H.; Li, C.Y.; Yan, F.L.; Song, Y.; Hai, G.F.; Jiao, Y.J.; Feng, Y.S. Network pharmacology study on the active components of Pterocypsela elata and the mechanism of their effect against cerebral ischemia. Drug Des. Dev. Ther. 2019, 13, 3009–3019.
[11]	Lan, R.; Zhang, Y.; Xiang, J.; Zhang, W.; Wang, G.H.; Li, W.W.; Xu, L.L.; Cai, D.F. Xiao-Xu-Ming decoction preserves mitochondrial integrity and reduces apoptosis after focal cerebral ischemia and reperfusion via the mitochondrial p53 pathway. J. Ethnopharmacol. 2014, 151, 307–316.
[12]	Jia, Z.; Tie, C.; Wang, C.; Wu, C.; Zhang, J. Perturbed lipidomic profiles in rats with chronic cerebral ischemia are regulated by Xiao-Xu-Ming decoction. Front. Pharmacol. 2019, 10, 264.
[13]	Ru, J.; Li, P.; Wang, J.; Zhou, W.; Li, B.; Huang, C.; Li, P.; Guo, Z.; Tao, W.; Yang, Y.; Xu, X.; Li, Y.; Wang, Y.; Yang, L. TCMSP: a database of systems pharmacology for drug discovery from herbal medicines. J. Cheminform. 2014, 6, 13.
[14]	Wang, Y.H.; Yang, Y.L.; Cheng, X.; Zhang, J.; Li, W.; Du, G.H. Xiao-Xu-Ming decoction extract regulates differentially expressed proteins in the hippocampus after chronic cerebral hypoperfusion. Neural Regen. Res. 2019, 14, 470–479.
[15]	Ma, Y.Z.; Li, L.; Song, J.K.; Niu, Z.R.; Liu, H.F.; Zhou, X.S.; Xie, F.S.; Du, G.H. A novel embolic middle cerebral artery occlusion model induced by thrombus formed in common carotid artery in rat. J. Neurol. Sci. 2015, 359, 275–279.
[16]	Cheng, X.; Yang, Y.L.; Yang, H.; Wang, Y.H.; Du, G.H. Kaempferol alleviates LPS-induced neuroinflammation and BBB dysfunction in mice via inhibiting HMGB1 release and down-regulating TLR4/MyD88 pathway. Int. Immunopharmacol. 2018, 56, 29–35.
[17]	Li, W.H.; Yang, Y.L.; Cheng, X.; Liu, M.; Zhang, S.S.; Wang, Y.H.; Du, G.H. Baicalein attenuates caspase-independent cells death via inhibiting PARP-1 activation and AIF nuclear translocation in cerebral ischemia/reperfusion rats. Apoptosis. 2020, 25, 354–369.
[18]	Yang, Y.L.; Liu, M.; Cheng, X.; Li, W.H.; Zhang, S.S.; Wang, Y.H.; Du, G.H. Myricitrin blocks activation of NF-κB and MAPK signaling pathways to protect nigrostriatum neuron in LPS-stimulated mice. J. Neuroimmunol. 2019, 337, 577049.
[19]	Ozaki, T.; Nakamura, H.; Kishima, H. Therapeutic strategy against ischemic stroke with the concept of neurovascular unit. Neurochem. Int. 2019, 126, 246–251.
[20]	Patel, R.A.G.; McMullen, P.W. Neuroprotection in the treatment of acute ischemic stroke. Prog. Cardiovasc. Dis. 2017, 59, 542–548.
[21]	Zhu, X.H.; Chen, S.Y.; Gao, T.M. Xiaoxuming decoction and stroke: a literature-based study. Acad J. First Med. Coll. PLA. 2002, 22, 564–565.
[22]	Luo, X.Y.; Chen, X.R.; Shen, X.L.; Yang, Z.H.; Du, G.H. Rapid identification and analysis of the active components of traditional Chinese medicine Xiaoxuming decoction for ischemic stroke treatment by integrating UPLC-Q-TOF/MS and RRLC-QTRAP MSn method. J. Chromatogr. B. 2019, 1124, 313–322.
[23]	Wang, C.H.; Jia, Z.X.; Wang, Z.; Hu, T.; Qin, H.L.; Du, G.H.; Wu, C.S.; Zhang, J.L. Pharmacokinetics of 21 active components in focal cerebral ischemic rats after oral administration of the active fraction of Xiao-Xu-Ming decoction. J. Pharm. Biomed. Anal. 2016, 122, 110–117.
[24]	Wang, Y.H. Activity evaluation of components and preparation of effective components group of Xiaoxuming decoction for anti-cerebral ischemic. China J. Chin. Mater. Med. 2011, 36, 2140. DOI:10.4268/cjcmm20111528.
[25]	Wang, Y.L.; Ding, C.G.; Du, K.H.; Xiao, Y.; Wu, C.S.; Zhang, J.L.; Qin, H.L.; Du, G.H. Identification of active compounds and their metabolites by high-performance liquid chromatography/electrospray ionization Fourier transform ion cyclotron resonance mass spectrometry from Xiao-Xu-Ming decoction (XXMD). Rapid Commun. Mass Spectrom. 2009, 23, 2724–2732.
[26]	Yang, S.; Shen, Y.; Lu, W.; Yang, Y.; Wang, H.; Li, L.; Wu, C.; Du, G. Evaluation and identification of the neuroprotective compounds of xiaoxuming decoction by machine learning: a novel mode to explore the combination rules in traditional Chinese medicine prescription. Biomed Res. Int. 2019, 2019, 6847685.
[27]	Wang, Y.H. Effects of the active components of Chinese herbal medicine Xiaoxuming Decoction on memory behavior and brain injury in rats with chronic cerebral ischemia. J. Chin. Integr. Med. 2012, 10, 91–99.
[28]	Du, X.; Lu, C.; He, X.L.; Du, G.H. Effects of active components group of Xiaoxuming decoction on brain mitochondria in cerebral ischemia/reperfusion rats during early recovery period. China J. Chin. Mater. Med. 2017, 42, 2139–2145.
[29]	Xiao, C. Xiao-Xu-Ming decoction extract alleviates LPS-induced neuroinflammation associated with down-regulating TLR4/MyD88 signaling pathway in vitro and in vivo. J. Chin. Pharm. Sci. 2019, 28, 88–99.
[30]	Yang, Y.L.; Zhang, S.S.; Liu, M.; Wang, Y.H.; Du, G.H. Xiao-Xu-Ming decoction extract ameliorates brain injury in rats with thrombotic focal ischemic stroke and understanding possible therapeutic targets using proteomics. J. Chin. Pharm. Sci. 2021, 30, 468–483.
[31]	Rahimifard, M.; Maqbool, F.; Moeini-Nodeh, S.; Niaz, K.; Abdollahi, M.; Braidy, N.; Nabavi, S.M.; Nabavi, S.F. Targeting the TLR4 signaling pathway by polyphenols: a novel therapeutic strategy for neuroinflammation. Ageing Res. Rev. 2017, 36, 11–19.
[32]	Ridder, D.A.; Schwaninger, M. NF-κB signaling in cerebral ischemia. Neuroscience. 2009, 158, 995–1006.
[33]	Greenberg, D.A. Cerebral angiogenesis: a realistic therapy for ischemic disease? Methods Mol. Biol. 2014, 1135, 21–24.
[34]	Xiang, Y.Y.; Yao, X.Q.; Wang, X.; Zhao, H.; Zou, H.Y.; Wang, L.; Zhang, Q.X. Houshiheisan promotes angiogenesis via HIF-1α/VEGF and SDF-1/CXCR4 pathways: in vivo and in vitro. Biosci. Rep. 2019, 39, BSR20191006. DOI:10.1042/bsr20191006.
[35]	Cárdenas-Rivera, A.; Campero-Romero, A.N.; Heras-Romero, Y.; Penagos-Puig, A.; Rincón-Heredia, R.; Tovar-Y-Romo, L.B. Early post-stroke activation of vascular endothelial growth factor receptor 2 hinders the receptor 1-dependent neuroprotection afforded by the endogenous ligand. Front. Cell Neurosci. 2019, 13, 270.
[36]	Zhou, J.; Du, T.; Li, B.M.; Rong, Y.; Verkhratsky, A.; Peng, L. Crosstalk between MAPK/ERK and PI3K/AKT signal pathways during brain ischemia/reperfusion. ASN Neuro. 2015, 7, 175909141560246.
[37]	Lahiani, A.; Brand-Yavin, A.; Yavin, E.; Lazarovici, P. Neuroprotective effects of bioactive compounds and MAPK pathway modulation in "ischemia"—stressed PC12 pheochromocytoma cells. Brain Sci. 2018, 8, 32.
[38]	Seil, F.J. Activity-dependent inhibitory synaptogenesis in cerebellar cultures. Brain Plast. 2016, 1, 207–214.
[39]	Binder, D.K.; Scharfman, H.E. Brain-derived neurotrophic factor. Growth Factors. 2004, 22, 123–131.
[40]	Lu, B.; Nagappan, G.; Lu, Y. BDNF and synaptic plasticity, cognitive function, and dysfunction Neurotrophic Factors. 2014, 220, 223–250.